Home Companies Catalysts Deep Dives
Ubrelvy ubrogepant APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaNeurology
Launch2019-12-23
US LOE2032-12-23
Peak Sales Est$1500M
Formulations[{"id":"ubrelvy-po","doses":"50mg, 100mg","route":"PO","setting":"PATIENT_SELF","frequency":"As need
Companies
ABBV (ORIGINATOR)100%
Mechanism: CGRP antagonist
Expert: Small molecule or antibody antagonizing calcitonin gene-related peptide (CGRP) or its receptor, blocking migraine signaling.
Everyday: Blocks a protein that causes migraines, preventing or stopping headache attacks.
Targets: ["CGRP"]
Revenue History
PeriodRevenue ($M)
2025$1,150M
Programs (1)
IndicationStageKey StudyRegional Status
Acute MigraineAPPROVEDACHIEVE I/II[{"stage":"APPROVED","region":"US","approval_date":"2019-12-23"}]
Notes
First oral CGRP antagonist for acute migraine. 2025 combined Ubrelvy+Qulipta revenue $2.3B.
Data from Supabase · Updated 2026-03-24